The DOI matches its Crossref record; 58 of the 59 references it cites were found in a registry or an index.
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Open accessAbstract
BACKGROUND: Somatic mutations have the potential to encode "non-self" immunogenic antigens. We hypothesized that tumors with a large number of somatic mutations due to mismatch-repair defects may be susceptible to immune checkpoint blockade. METHODS: We conducted a phase 2 study to evaluate the clinical activity of pembrolizumab, an anti-programmed death 1 immune checkpoint inhibitor, in 41 patients with progressive metastatic carcinoma with or without mismatch-repair deficiency. Pembrolizumab was administered intravenously at a dose of 10 mg per kilogram of body weight every 14 days in patients with mismatch repair-deficient colorectal cancers, patients with mismatch repair-proficient colorectal cancers, and patients with mismatch repair-deficient cancers that were not colorectal. The coprimary end points were the immune-related objective response rate and the 20-week immune-related progression-free survival rate. RESULTS: The immune-related objective response rate and immune-related progression-free survival rate were 40% (4 of 10 patients) and 78% (7 of 9 patients), respectively, for mismatch repair-deficient colorectal cancers and 0% (0 of 18 patients) and 11% (2 of 18 patients) for mismatch repair-proficient colorectal cancers. The median progression-free survival and overall survival were not reached in the cohort with mismatch repair-deficient colorectal cancer but were 2.2 and 5.0 months, respectively, in the cohort with mismatch repair-proficient colorectal cancer (hazard ratio for disease progression or death, 0.10 [P<0.001], and hazard ratio for death, 0.22 [P=0.05]). Patients with mismatch repair-deficient noncolorectal cancer had responses similar to those of patients with mismatch repair-deficient colorectal cancer (immune-related objective response rate, 71% [5 of 7 patients]; immune-related progression-free survival rate, 67% [4 of 6 patients]). Whole-exome sequencing revealed a mean of 1782 somatic mutations per tumor in mismatch repair-deficient tumors, as compared with 73 in mismatch repair-proficient tumors (P=0.007), and high somatic mutation loads were associated with prolonged progression-free survival (P=0.02). CONCLUSIONS: This study showed that mismatch-repair status predicted clinical benefit of immune checkpoint blockade with pembrolizumab. (Funded by Johns Hopkins University and others; ClinicalTrials.gov number, NCT01876511.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A seminal phase II trial from 2015 showed that ICB with the anti-PD-1 antibody pembrolizumab resulted in durable responses in more than 50% of patients with dMMR/MSI-H but not in pMMR/MSS mCRC.100”
From Current and emerging concepts for systemic treatment of metastatic colorectal cancer (2025) · cites this paper as [100]
In the citing paper
“This was particularly noted in anti-CTLA-4-treated melanoma patients whose tumors displayed neo-antigens (87) and similarly in anti-PD-1-treated patients with colorectal cancers or non-small cell lung cancers that were mismatch-repair deficient or had high mutation rates, respectively (78, 86).”
From Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations (2018) · cites this paper as [78]
In the citing paper
“Anti-PD-1 therapies have also received approval for treatment of patients with cancer who are diagnosed with tumors that have microsatellite instabilityhigh (MSI-H )/mismatch-repair defi ciency (dMMR; refs.47,48 ) or high tumor mutational burden (TMB-high) regardless of tumor type ( 49 ).”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [47]
In the citing paper
“An initial study in patients with colorectal cancer demonstrated significantly higher rates of response to pembrolizumab in dMMR patients compared with MMR-proficient patients (47), a finding that was later extended to multiple tumor types (48).”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [47]
In the citing paper
“Previous reports have shown that the total number of somatic coding mutations in a cancer genome correlates with response to ICB (7, 8, 10–12, 17).”
From Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy (2018) · cites this paper as [8]
In the citing paper
“Response rates to ICI treatment vary widely among different cancers, ranging from greater than 80% in patients with refractory Hodgkin's lymphoma to little or no response in patients with mismatch repair-proficient colorectal cancer (76, 77); many tumor indications fall within a response rate range of 20% to 40% (78).”
From Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance (2021) · cites this paper as [77]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Self-citationComprehensive molecular characterization of human colon and rectal cancer
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11252 · Cited by 8,499
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
Self-citationMutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Comprehensive molecular characterization of gastric adenocarcinoma
The Cancer Genome Atlas Research Network (2014) · Nature · doi:10.1038/nature13480 · Cited by 6,498
Integrated genomic characterization of endometrial carcinoma
The Cancer Genome Atlas Research Network, & Levine, D. A. (2013) · Nature · doi:10.1038/nature12113 · Cited by 5,784
Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
Herbst, R. S., Soria, J.-C., Kowanetz, M., Fine, G. D., Hamid, O., Gordon, M. S., Sosman, J. A., McDermott, D. F., Powderly, J. D., Gettinger, S. N., et al. (2014) · Nature · doi:10.1038/nature14011 · Cited by 5,231
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
Bettegowda, C., Sausen, M., Leary, R. J., Kinde, I., Wang, Y., Agrawal, N., Bartlett, B. R., Wang, H., Luber, B., Alani, R. M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007094 · Cited by 5,067
Self-citationGenetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
Snyder, A., Makarov, V., Merghoub, T., Yuan, J., Zaretsky, J. M., Desrichard, A., Walsh, L. A., Postow, M. A., Wong, P., Ho, T. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406498 · Cited by 4,286
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
Ansell, S. M., Lesokhin, A. M., Borrello, I., Halwani, A. S., Scott, E. C., Gutierrez, M. E., Schuster, S. J., Millenson, M. M., Cattry, D., Freeman, G. J., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1411087 · Cited by 3,621
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
Hamid, O., Robert, C., DAUD, A. I., Hodi, F. S., Hwu, W., Kefford, R. F., Wolchok, J. D., Hersey, P., Joseph, R. W., Weber, J. S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305133 · Cited by 3,427
Wolchok, J. D., Hoos, A., O'Day, S. J., Weber, J. S., Hamid, O., Lebbé, C., Maio, M., Binder, M., Bohnsack, O., Nichol, G. M., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1624 · Cited by 3,214
Brahmer, J. R., Drake, C. G., WOLLNER, I. S., Powderly, J. D., Picus, J., Sharfman, W. H., Stankevich, E., Pons, A., Salay, T. M., McMiller, T. L., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.7609 · Cited by 2,967
Self-citationNishimura, H., Nose, M., Hiai, H., Minato, N., & Honjo, T. (1999) · Immunity · doi:10.1016/s1074-7613(00)80089-8 · Cited by 2,749
Circulating mutant DNA to assess tumor dynamics
Diehl, F., Schmidt, K., Choti, M. A., Romans, K. E., Goodman, S. N., Li, M., Thornton, K. A., Agrawal, N., Sokoll, L. J., Szabo, S., et al. (2008) · Nature Medicine · doi:10.1038/nm.1789 · Cited by 2,746
Self-citationMicrosatellite Instability in Colorectal Cancer
Boland, C. R., & Goel, A. (2010) · Gastroenterology · doi:10.1053/j.gastro.2009.12.064 · Cited by 2,456
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
Powles, T. B., Eder, J. P., Fine, G. D., Braiteh, F. S., Loriot, Y., Cruz, C., Joaquim Bellmunt, B., Burris, H. A., Petrylak, D. P., Teng, S.-L. M., et al. (2014) · Nature · doi:10.1038/nature13904 · Cited by 2,410
Taube, J. M., Klein, A., Brahmer, J. R., Xu, H., Pan, X., Kim, J. H., Chen, L., Pardoll, D. M., Topalian, S. L., & Anders, R. A. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3271 · Cited by 2,324
Self-citationLynch, H. T., & de la Chapelle, A. (2003) · New England Journal of Medicine · doi:10.1056/nejmra012242 · Cited by 2,240
Topalian, S. L., Sznol, M., McDermott, D. F., Kluger, H. M., Carvajal, R. D., Sharfman, W. H., Brahmer, J. R., Lawrence, D. P., Atkins, M. B., Powderly, J. D., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.0105 · Cited by 2,222
Self-citationLiquid Biopsies: Genotyping Circulating Tumor DNA
Diaz, L. A., & Bardelli, A. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.2011 · Cited by 2,210
Self-citationCheckpoint blockade cancer immunotherapy targets tumour-specific mutant antigens
Gubin, M. M., Zhang, X., Schuster, H., Caron, E., Ward, J. P., Noguchi, T., Ivanova, Y., Hundal, J., Arthur, C. D., Krebber, W.-J., et al. (2014) · Nature · doi:10.1038/nature13988 · Cited by 1,974
Landon, M., Saam, J. R., Brown, K. L., Moyes, K., Evans, B. A., & WENSTRUP, R. J. (2015) · Oncology · doi:10.1159/000430097 · Cited by 1,943
Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma
Herman, J. G., Umar, A., Polyák, K., Graff, J. R., Ahuja, N., Issa, J. J., Markowitz, S. D., Willson, J. K. V., Hamilton, S. R., Kinzler, K. W., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.12.6870 · Cited by 1,887
Self-citationAutoimmune Dilated Cardiomyopathy in PD-1 Receptor-Deficient Mice
Nishimura, H., Okazaki, T., Tanaka, Y., Nakatani, K., Hara, M., Matsumori, A., Sasayama, S., Mizoguchi, A., Hiai, H., Minato, N., et al. (2001) · Science · doi:10.1126/science.291.5502.319 · Cited by 1,868
Llosa, N. J., Cruise, M., Tam, A., Wicks, E. C., Hechenbleikner, E. M., Taube, J. M., Blosser, R. L., Fan, H., Wang, H., Luber, B. S., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0863 · Cited by 1,487
Self-citationCo-inhibitory molecules of the B7–CD28 family in the control of T-cell immunity
Chen, L. (2004) · Nature reviews. Immunology · doi:10.1038/nri1349 · Cited by 1,285
Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing
Yadav, M., Jhunjhunwala, S., Phung, Q. T., Lupardus, P., Tanguay, J., Bumbaca, S., Franci, C., Cheung, T. K., Fritsche, J., Weinschenk, T., et al. (2014) · Nature · doi:10.1038/nature14001 · Cited by 1,186
Palles, C., Cazier, J., Howarth, K. M., Domingo, E., Jones, A. M., Broderick, P., Kemp, Z., Spain, S. L., Guarino, E., Salguero, I., et al. (2012) · Nature Genetics · doi:10.1038/ng.2503 · Cited by 1,008
Kim, H., Jen, J., Vogelstein, B., & Hamilton, S. R. (1994) · PubMed Central · Cited by 809
Self-citationLundegaard, C., Lamberth, K., Harndahl, M. N., Buus, S., Lund, O., & Nielsen, M. (2008) · Nucleic Acids Research · doi:10.1093/nar/gkn202 · Cited by 808
Melanoma genome sequencing reveals frequent PREX2 mutations
Berger, M. F., Hodis, E., Heffernan, T. P., Deribe, Y. L., Lawrence, M. S., Protopopov, A., Ivanova, E., Watson, I. R., Nickerson, E., Ghosh, P., et al. (2012) · Nature · doi:10.1038/nature11071 · Cited by 756
Linnemann, C., van Buuren, M. M., Bies, L., Verdegaal, E. M. E., Schotte, R., Calis, J. J. A., Behjati, S., Velds, A., Hilkmann, H., Atmioui, D. E., et al. (2014) · Nature Medicine · doi:10.1038/nm.3773 · Cited by 688
Durable Cancer Regression Off-Treatment and Effective Reinduction Therapy with an Anti-PD-1 Antibody
Lipson, E. J., Sharfman, W. H., Drake, C. G., WOLLNER, I. S., Taube, J. M., Anders, R. A., Xu, H., Yao, S., Pons, A., Chen, L., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2625 · Cited by 551
Self-citationDeficient mismatch repair system in patients with sporadic advanced colorectal cancer
Koopman, M., Kortman, G. A. M., Mekenkamp, L. J., Ligtenberg, M. J. L., Hoogerbrugge, N., Antonini, N. F., Punt, C. J. A., & van Krieken, J. H. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6604867 · Cited by 521
Histopathological Identification of Colon Cancer with Microsatellite Instability
Alexander, J., Watanabe, T., Wu, T., Rashid, A., Li, S., & Hamilton, S. R. (2001) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)63994-6 · Cited by 510
The mutation spectrum revealed by paired genome sequences from a lung cancer patient
Lee, W., Jiang, Z., Liu, J., Haverty, P. M., Guan, Y., Stinson, J., Yue, P., Zhang, Y., Pant, K. P., Bhatt, D., et al. (2010) · Nature · doi:10.1038/nature09004 · Cited by 492
Dolcetti, R., Viel, A., Doglioni, C., Russo, A. G., Guidoboni, M., Capozzi, E., Vecchiato, N., Macrì, E., Fornasarig, M., & Boiocchi, M. (1999) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)65436-3 · Cited by 480
DETECTION OF CIRCULATING TUMOR DNA IN EARLY AND LATE STAGE HUMAN MALIGNANCIES
Bettegowda, C., Sausen, M., Leary, R. J., Kinde, I., Agrawal, N., Bartlett, B. R., Wang, H., Luber, B. S., Kinzler, K. W., Vogelstein, B., et al. (2014) · Neuro-Oncology · doi:10.1093/neuonc/nou206.24 · Cited by 441
Self-citationPersonalized genomic analyses for cancer mutation discovery and interpretation
Jones, S., Anagnostou, V., Lytle, K., Parpart-Li, S. T., Nesselbush, M. C., Riley, D. R. J., Shukla, M., Chesnick, B., Kadan, M., Papp, E., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aaa7161 · Cited by 418
Self-citationEpitope Landscape in Breast and Colorectal Cancer
Segal, N. H., Parsons, D. W., Peggs, K. S., Velculescu, V., Kinzler, K. W., Vogelstein, B., & Allison, J. P. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-3095 · Cited by 416
Self-citationJones, S. (2002) · Human Molecular Genetics · doi:10.1093/hmg/11.23.2961 · Cited by 399
Young, J. P., Simms, L. A., Biden, K. G., Wynter, C. V. A., Whitehall, V., Karamatic, R., George, J., Goldblatt, J., Walpole, I., Robin, S.-A., et al. (2001) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)63062-3 · Cited by 358
Goldstein, J., Tran, B., Ensor, J., Gibbs, P., Wong, H. L., Wong, S. F., Vilar, E., Tie, J., Broaddus, R., Kopetz, S., et al. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu100 · Cited by 288
Lundegaard, C., Lund, O., & Nielsen, M. (2008) · Bioinformatics · doi:10.1093/bioinformatics/btn128 · Cited by 254
Timmermann, B., Kerick, M., Roehr, C., Fischer, A., Isau, M., Boerno, S. T., Wunderlich, A., Barmeyer, C., Seemann, P., Koenig, J., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0015661 · Cited by 246
Increased mutation rate at the hprt locus accompanies microsatellite instability in colon cancer.
Eshleman, J. R., Lang, E. Z., Bowerfind, G. K., Parsons, R. E., Vogelstein, B., Willson, J. K. V., Veigl, M. L., Sedwick, W. D., & Markowitz, S. D. (1995) · PubMed · Cited by 242
Self-citationHuman papillomavirus as a prognostic factor in carcinoma of the penis
Bezerra, A. L. R., Lopes, A., Hidalgo, G. S., Ribeiro, K. B., Latorre, M. R. D. O., & Villa, L. L. (2001) · Cancer · doi:10.1002/1097-0142(20010615)91:12 · Cited by 206
Garg, K., Leitão, M. M., Kauff, N. D., Hansen, J., Kosarin, K., Shia, J., & Soslow, R. A. (2009) · The American Journal of Surgical Pathology · doi:10.1097/pas.0b013e318197a046 · Cited by 191
Meltzer, S. J., Yin, J., Manin, B., Rhyu, M. G., Cottrell, J. R., Hudson, E., Redd, J. L., Krasna, M. J., Abraham, J. M., & Reid, B. J. (1994) · PubMed · Cited by 140
Prognostic value of microsatellite instability in resectable pancreatic cancer.
Nakata, B., Wang, Y. Q., Yashiro, M., Nishioka, N., Tanaka, H., Ohira, M., Ishikawa, T., Nishino, H., & Hirakawa, K. (2002) · PubMed · Cited by 134
Genetic steps in colorectal cancer
Bodmer, W. F., Bishop, D. T., & Karran, P. (1994) · Nature Genetics · doi:10.1038/ng0394-217 · Cited by 129
Gastrointestinal cancer of the microsatellite mutator phenotype pathway
Yamamoto, H., Imai, K., & Perucho, M. (2002) · Journal of Gastroenterology · doi:10.1007/s005350200015 · Cited by 64
Defective DNA mismatch repair in long-term (≥ 3 years) survivors with pancreatic cancer
Maple, J. T., Smyrk, T. C., Boardman, L. A., Johnson, R., Thibodeau, S. N., Chari, S. T., & Real, F. X. (2005) · Pancreatology · doi:10.1159/000085275 · Cited by 46
DNA Mismatch Repair Deficiency in Ampullary Carcinoma
Agaram, N. P., Shia, J., Tang, L. H., & Klimstra, D. S. (2010) · American Journal of Clinical Pathology · doi:10.1309/ajcpgdde8plldrcc · Cited by 43
The analysis of microsatellite instability in extracolonic gastrointestinal malignancy
Williams, A. S., & Huang, W. (2013) · Pathology · doi:10.1097/pat.0b013e3283653307 · Cited by 27
Flagged first, then by citations
1 of the 59 references couldn’t be matched to a known paper.
Research works printed but not linked: 4
- Eshleman JR, 1995, Oncogene, 10, 33
- Meltzer SJ, 1994, Cancer Res, 54, 3379
- Nakata B, 2002, Clin Cancer Res, 8, 2536
- Kim H, 1994, Am J Pathol, 145, 148
Cited by
Sorted by citations
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645
Self-citationPembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198
Self-citationElements of cancer immunity and the cancer–immune set point
Chen, D. S., & Mellman, I. (2017) · Nature · doi:10.1038/nature21349 · Cited by 5,352
Dekker, E., Tanis, P. J., Vleugels, J. L. A., Kasi, P. M., & Wallace, M. B. (2019) · The Lancet · doi:10.1016/s0140-6736(19)32319-0 · Cited by 5,313
Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response
Jiang, P., Gu, S., Pan, D., Fu, J., Sahu, A., Hu, X., Li, Z., Traugh, N., Bu, X., Li, B., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0136-1 · Cited by 5,179
Metadata
- Authors
- Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., Biedrzycki, B., Donehower, R. C., Zaheer, A., Fisher, G. A., Crocenzi, T. S., Lee, J. J., Duffy, S. M., Goldberg, R. M., de la Chapelle, A., Koshiji, M., Bhaijee, F., Huebner, T., Hruban, R. H., Wood, L. D., Cuka, N., Pardoll, D. M., Papadopoulos, N., Kinzler, K. W., Zhou, S., Cornish, T. C., Taube, J. M., Anders, R. A., Eshleman, J. R., Vogelstein, B., & Diaz, L. A.
- Affiliations
- Swim Across America (US)
- Howard Hughes Medical Institute (US)
- Johns Hopkins University (US)
- Providence Portland Medical Center (US)
- University of Pittsburgh (US)
- The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (US)
- From the Swim Across America Laboratory (D.T.L., J.N.U., B.R.B., L.A.D.), Sidney Kimmel Comprehensive Cancer Center (D.T.L., J.N.U., H.W., H.K., A.D.E., A.D.S., B.S.L., N.S.A., D.L., B.B., R.C.D., D.M.P., N.P., K.W.K., S.Z., B.V., L.A.D.), Ludwig Center and Howard Hughes Medical Institute (B.R.B., A.D.S., N.P., K.W.K., S.Z., B.V., L.A.D.), and the Departments of Radiology (A.Z.) and Pathology (F.B., T.H., R.H.H., L.D.W., N.C., T.C.C., J.M.T., R.A.A., J.R.E.), Johns Hopkins University School of Medicine,...
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- ORCID
- Le, Dung T.
- Wang, Hao
- Bartlett, Bjarne R.
- Kemberling, Holly
- Skora, Andrew D.
- Azad, Nilofer S.
- Donehower, Ross C.
- Zaheer, Atif
- Fisher, George A.
- Crocenzi, Todd S.
- Lee, James J.
- Duffy, Steven M.
- Goldberg, Richard M.
- Bhaijee, Feriyl
- Huebner, Thomas
- Hruban, Ralph H.
- Wood, Laura D.
- Pardoll, Drew M.
- Papadopoulos, Nickolas
- Kinzler, Kenneth W.
- Zhou, Shibin
- Cornish, Toby C.
- Taube, Janis M.
- Anders, Robert A.
- Eshleman, James R.
- Vogelstein, Bert
- Diaz, Luis A.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-06-25
- Volume
- 372
- Issue
- 26
- Pages
- 2509-2520
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC4481136
- OpenAlex
- W1940241680
- Cited by
- 9,377
- References
- 59
- Citations by year
- 2026: 450 · 2025: 577 · 2024: 680 · 2023: 864 · 2022: 958 · 2021: 1155 · 2020: 1123 · 2019: 911 · 2018: 935 · 2017: 878 · 2016: 668 · 2015: 167
- FWCI
- 382.77
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (CA67941, CA163672, CA16058, CA 57345, CA43460, K23CA163672, U01CA067941, R37CA043460, R01CA057345, R01CA067941, P50CA062924, R37CA057345, P30CA016058, P30CA006973)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Keywords
- anti-PD-1 therapy, pembrolizumab, mismatch repair deficiency, immune checkpoint inhibitors, somatic mutations, tumor mutational burden, colorectal cancer, metastatic carcinoma, predictive biomarkers, exome sequencing, cancer immunotherapy, progression-free survival, overall survival
- MeSH terms
- Adenocarcinoma, Adult, Aged, Antineoplastic Agents, Female, Humans, Male, Middle Aged, Neoplasm Metastasis, Colorectal Neoplasms, Disease-Free Survival, Kaplan-Meier Estimate, DNA Mismatch Repair, Programmed Cell Death 1 Receptor, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
